1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Gland Pharma Limited

Gland Pharma Limited

GLAND.NS
Gland Pharma LimitedIN flagNational Stock Exchange of India
2,463.20
INR
+0.90
- -
406.33BMarket Cap
Gland Pharma Limited
GLAND.NS
(National Stock Exchange of India)

Recent

price

2,463.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
96.77
122.07
157.5
216.58
267.08
218.17
342.54
340.92
390.29
347.21
Revenue per Share
19.66
27.67
47.33
63.07
73.81
47.44
46.9
42.4
62.35
46.75
Basic EPS, GAAP
7.16
3.03
31.01
23.8
16.37
8.56
36.34
31.6
32.59
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
20
18
- -
Dividend per Share
111.24
138.91
186.25
255.51
319.87
366.37
413.13
435.42
1
- -
Book Value per Share
147.62
175.28
223.31
373.44
435.27
482.7
508.15
533.96
604.22
- -
Tangible Book Value per Share
163
163
163
158
164
165
165
165
165
165
Basic Weighted Avg Shares
15,801
19,931
25,718
34,236
43,841
35,919
56,417
56,165
64,306
57,204
Sales/Revenue/Turnover
29
30.8
33.54
35.16
31.94
24.22
17.66
15.86
18.75
17.22
Operating Margin (%)
784
821
946
988
1,103
1,467
3,446
3,779
4,237
3,870
Depreciation Expense
3,211
4,519
7,729
9,970
12,117
7,810
7,725
6,985
10,273
7,702
Net Income, GAAP
35.98
34.16
22.16
25.31
25.14
25.94
31.79
34.27
29.86
33.44
Effective Tax Rate (%)
20.32
22.67
30.05
29.12
27.64
21.74
13.69
12.44
15.98
13.46
Profit Margin (%)
13,530
18,247
24,873
46,111
52,701
61,717
42,468
52,181
59,184
- -
Working Capital
66
60
50
47
45
37
1,412
1,072
932
- -
LT Debt
24,104
28,620
36,462
59,032
71,576
79,587
87,238
91,507
103,580
- -
Total Equity
- -
15.23
20.54
18.74
15.99
8.55
7.98
6.28
8.37
- -
Return on Invested Capital (%)
- -
22.13
29.23
28.18
26.11
13.92
11.92
9.9
26.98
203.5
Return on Capital (%)
- -
22.12
29.11
28.16
26.09
13.85
12.04
9.99
28.58
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
2,066
- -
LT Borrowings
- -
777
- -
LT Finance Leases
- -
295
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
165
- -
Market Capitalization
293,099
262,331
302,096

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
67,829
- -
Cash, Cash Equivalents & STI
- -
29,522
- -
Accounts Receivable, Net
- -
15,165
- -
Inventories
- -
16,852
- -
Total Current Liabilities
- -
15,648
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
2,066
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.03%
13.19%
Free Cash Flow
- -
47.78%
3.15%
Net Income, GAAP
- -
4.48%
47.07%
Sales/Revenue/Turnover
- -
16.22%
14.5%
Total Cash Common Dividend
- -
- -
-10%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,087
13,734
15,452
15,145
56,417
2025
14,017
14,058
13,841
14,249
56,165
2026
15,056
16,954
17,428
- -
64,306

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11.79
11.78
11.65
- -
46.9
2025
8.73
9.93
12.42
11.32
42.4
2026
13.08
15.87
22.26
- -
62.35

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
20
2026
- -
- -
- -
- -
18
Similar Companies
Santen Pharmaceutical Co., Ltd. (4536.T)
BioDelivery Sciences Intl, Inc. Wrrt (BDSIW)
PT Kalbe Farma Tbk. (PTKFF)
Novo Nordisk A/S (NOVC.DE)
Grifols, S.A. (GIFOF)
Santen Pharmaceutical Co., Ltd. (SNPHY)
Business
Gland Pharma Limited manufactures and markets complex generic injectable pharmaceuticals. The company produces sterile injectables including oncology and ophthalmics; complex injectables such as NCE-1s, First-to-File products and 505(b)(2) filings; formulations delivered via liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops; and specialized products like peptides, long-acting injectables, suspensions and hormonal therapies, with new delivery systems including pens and cartridges in development. It supplies products across therapeutic categories encompassing anti-infectives, anti-neoplastics, blood-related therapies, cardiac, gastrointestinal, hormones, neuro/CNS, pain and analgesics, respiratory, and vitamins, minerals and nutrients; and provides contract development and manufacturing organization (CDMO) services. Gland Pharma operates in over 60 countries including the United States, Europe, Canada, Australia, New Zealand, India and other markets. Founded in 1978 and headquartered in Hyderabad, India, the company functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd. Recent developments include a 250% expansion of GLP-1/cartridge production capacity from 40 million to 140 million units to address demand for diabetes and obesity treatments; launch of its first partnered GLP-1 product, Liraglutide; new product launches comprising four molecules in Q4 FY25; leadership changes with Srinivas Sadu appointed Executive Chairman and Shyamakant Giri as Chief Executive Officer in January 2025, alongside Satnam Singh Loomba joining as Chief Operating Officer in May 2024; and targeted annual revenue growth of 14-15% supported by expansions and a strengthened complex injectables pipeline.